005 |
|
20221103120837.0 |
020 |
|
|a0230584047
|
020 |
|
|a9780230584044
|
024 |
7
|
|a10.1057/9780230584044|2doi
|
040 |
|
|aUKPGM|beng|cUKPGM|dNOU
|
049 |
|
|aAPTA
|
050 |
14
|
|aKJE6778|b.K73 2008eb
|
082 |
04
|
|a344.2404/232|222
|
100 |
1
|
|aKrapohl, Sebastian,|d1978-
|
245 |
10
|
|aRisk regulation in the single market|h[electronic resource] :|bthe governance of pharmaceuticals and foodstuffs in the European Union /|cSebastian Krapohl.
|
260 |
|
|aBasingstoke [England] ;|aNew York :|bPalgrave Macmillan,|c2008.
|
300 |
|
|axiii, 225 p. :|bill. ;|c23 cm.
|
440 |
0
|
|aPalgrave studies in European Union politics
|
504 |
|
|aIncludes bibliographical references (p. 195-220) and index.
|
505 |
0
|
|aIntroduction : the need for a systematic analysis of supranational risk regulation -- Functional pressure and path-dependencies : the emergence and development of supranational regulatory regimes -- Efficiency and legitimacy : the evaluation of supranational regulatory regimes -- From national crises to a strong supranational regime : the developmentof pharmaceutical authorisation in Europe-- A strong regulatory regulatory network : -- The evaluation of the European regulatory regime forpharmaceuticals -- From an early single market to a crisis of consumerconfidence : the development of foodstuff regulation in Europe -- A weak supranational agency : the evaluation of the European regulatory regime for foodstuffs -- A comparison of pharmaceutical and foodstuff regulation in Europe.
|
520 |
|
|aWhy do the regulatory institutions of the EU look different across similar policy areas? Why do they work with different degrees of success? This book provides a theoretically driven comparisonof two importantareas of EU risk regulation. Whereas the functional demands for supranational risk regulation are similar in pharmaceutical and foodstuff regulation, the efficiency of the two respective regulatory regimes has differed widely during the last 15 years. The EU regulatory regime for pharmaceuticals has managed to establish a single market for highly innovative pharmaceuticals - including b1 sred biotechnology b2 s. In contrast, the single market for foodstuffs was shattered by theBSE crisis, and b1 sgreen biotechnology b2 s - that is, GMOs and Gen-Food - is still highly contested. As this book demonstrates, these differences in the efficiency and legitimacy of EU risk regulation can be traced back tothe different institutional designs of the respective regimes, which in turn result from different developmental paths.
|
533 |
|
|aElectronic reproduction.|bBasingstoke, England :|cPalgrave Macmillan,|d2009.|nMode of access:World Wide Web.|nSystem requirements: Web browser.|nTitle from title screen (viewed on Mar. 3, 2009).|nAccess may berestricted to users at subscribing institutions.
|
650 |
0
|
|aDrugs|xLaw and legislation|zEuropean Union countries.
|
650 |
0
|
|aFood law and legislation|zEuropean Union countries.
|
655 |
7
|
|aElectronic books.|2local
|
710 |
2
|
|aPalgrave Connect (Online service)
|
776 |
1
|
|cOriginal|z9780230537651|z0230537650|w(DLC) 2008030198|w(OCoLC)236082328
|
809 |
|
|pEB|dKJE6778|eK89|y2008
|
856 |
40
|
|3Palgrave Connect|uhttp://www.palgraveconnect.com/doifinder/10.1057/9780230584044|zaccess to fulltext (Palgrave)
|